title: [Evaluation of prazosin in the treatment of benign hypertrophy of the prostate. A case-control study].
abstract: A control-case study conducted in 56 patients, all diagnosed with benign prostate hypertrophy of which 36 were Prazosin-treated patients and the remaining 20 were controls. The patient's mictional signs and symptoms as well as flow parameters were monitored at 3 and 6 months, respectively. We conclude that Prazosin is an alpha-blocker useful in early prostate disorders and when no obstructive urological disease is present.
authors.affiliation: Servicio de Urología, Hospital Rio Carrion, Palencia.
authors.forename: M
authors.initials: M
authors.lastname: Adriazola Semino
authors.forename: E
authors.initials: E
authors.lastname: García Cobo
authors.forename: I
authors.initials: I
authors.lastname: De la Calle Muñoz
authors.forename: E
authors.initials: E
authors.lastname: Tejeda Bañez
authors.forename: F
authors.initials: F
authors.lastname: Romero
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy*
chemical_list: D011224:Prazosin